Title
Category
Credits
Event date
Cost
2023 Women’s Masterclass On Demand
  • CMHC
  • 12.00 ACPE Pharmacy
  • 12.00 AMA PRA Category 1 Credit™
  • 12.00 ANCC
  • 12.00 Participation
$0.00
The recordings from the 2023 Women’s Cardiometabolic Health and Wellness Masterclass are now available. Led by co-chairs Pam R. Taub, MD and Erin D. Michos, MD, MHS, experts in a multitude of women's health topics explored the significant differences in risk factors, symptom presentation, preventive strategies, and treatment for cardiometabolic diseases in women, as well as important implications for patient care.
Breaking Through Inertia: How to Initiate and Maintain Insulin Therapy in Patients with Type 2 Diabetes
  • CMHC
  • 1.50 AAFP
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
$0.00
This interactive infographic covers a variety of topics surrounding the role of insulin therapy in type 2 diabetes (T2D) management, including practical pearls for initiation and maintenance of insulin therapy, how insulin therapy fits in with other T2D treatment options, and emerging insulin options. The information is presented in an interactive format, which contains a mix of high-impact visuals, infographics, expert faculty videos, as well as resources and suggested readings, all organized into different segments to facilitate learning.
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
  • CMHC
  • TME
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. MASH represents a metabolic-driven array of multi-organ pathology that intersects with obesity, prediabetes, type 2 diabetes, and cardiovascular ailments. Many agents are currently in development for treatment of MASH, including glucagon-like peptide-1 receptor agonists (GLP1-Ras).
Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk: A Paradigm Shift
  • CMHC
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
$0.00
Effectively and safely lowering LDL-C is essential to prevent and reduce the risk of recurrent ASCVD events. Despite advancements in LDL-C lowering therapies, achieving LDL-C targets remains suboptimal due to clinical inertia and patient non-adherence, contributing to patient's residual ASCVD risk. The landscape of LDL-C lowering therapies is rapidly evolving, with several new and emerging agents that may help bridge these gaps.

Pages